Published in J Clin Invest on April 01, 2008
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
CD28 co-stimulation down regulates Th17 development. PLoS One (2009) 1.28
Public awareness and views on unlicensed use of medicines in children. Br J Clin Pharmacol (2008) 0.98
Immunotoxicity of monoclonal antibodies. MAbs (2009) 0.97
CCC meets ICU: redefining the role of critical care of cancer patients. BMC Cancer (2010) 0.90
Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med (2009) 0.87
The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries. BMC Public Health (2011) 0.85
Dynamics of a cytokine storm. PLoS One (2012) 0.85
Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev (2013) 0.84
Granzyme B- and Fas ligand-mediated cytotoxic function induced by mitogenic CD28 stimulation of human memory CD4+ T cells. J Leukoc Biol (2012) 0.84
Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev (2014) 0.80
IL-2/anti-IL-2 complex: a novel strategy of in vivo regulatory T cell expansion in renal injury. J Am Soc Nephrol (2013) 0.77
Approaches to modelling the human immune response in transition of candidates from research to development. J Immunol Res (2014) 0.77
Translating Treg Therapy in Humanized Mice. Front Immunol (2015) 0.76
CD28 ligation increases macrophage suppression of T-cell proliferation. Cell Mol Immunol (2012) 0.76
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX (2016) 0.75
Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. PLoS One (2017) 0.75
Cancer and Aging - the Inflammatory Connection. Aging Dis (2017) 0.75
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet (2006) 6.55
"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol (2007) 2.11
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci U S A (2006) 1.75
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol (2007) 1.29
Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice. Blood (2006) 1.23
Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol (2003) 1.01
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest (2008) 0.98
The Northwick Park tragedy--protecting healthy volunteers in future first-in-man trials. J Clin Pharm Ther (2007) 0.96
Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol (2006) 0.96
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum (2013) 0.86